Bristol-Myers Squibb Says US FDA Accepts New Drug Application for Mezigdomide Combination Therapy in Myeloma
() -- Bristol-Myers Squibb (BMY) said Monday the US Food and Drug Administration has accepted a new drug application for mezigdomide, in combination with carfilzomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma. The filing was based on a phase 3 study that demonstrated t